secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMARIN CORP PLCUK (AMRN)
CIK:        0000897448
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0000950170-24-040675
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent
-------------------------------------------------------------------------------

- EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.
- Amarin successfully defended separate VAZKEPA patent (expires June 2033) against third-party opposition at EPO.
- Legacy patent exclusivity from ANCHOR study extended via SPCs until June 2035.
- Regulatory exclusivity for VAZKEPA in Europe runs until March 2031, layering with patent protections.
- CEO Patrick Holt says extended runway enhances commercial and growth potential for VAZKEPA in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/0000950170-24-040675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/amrn-20240403.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-040675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer